Thalidomide-O-amido-C6-NH2 (TFA)

Thalidomide-O-amido-C6-NH2 (TFA)

• CAS Number: 1950635-14-9
• UNSPSC Description: Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs[1].
• Target Antigen: Apoptosis; Autophagy; E3 Ligase Ligand-Linker Conjugates
• Type: Reference compound
• Related Pathways: Apoptosis;Autophagy;PROTAC
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/E3_Ligase_Ligand-Linker_Conjugates_25_Trifluoroacetate.html
• Purity: 99.82
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(NCCCCCCN)COC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O.O=C(O)C(F)(F)F
• Molecular Weight: 544.48
• References & Citations: [1]Bradner J, et al. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses. WO 2017024318 A1
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, stored under nitrogen)
• Clinical Information: No Development Reported